Clinical trials: in Norway
Bladder Cancer, Urinary Bladder Neoplasms
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the…
- Trial name
- NCT07222488
- Testing
- MK-3120
- Where
- 17 sites in United States, Austria and 10 more
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Anxiety, Depression
Mental Health INtervention With Digital APPlications (MIND-APP): Evaluating the Effectiveness of the Tankevirus and Grubl Mental Health Apps
The MIND-APP trial is a 3-arm randomized controlled trial (1:1:1 allocation) conducted fully remotely via a bespoke smartphone research platform.
- Trial name
- MIND-APP (NCT07627204)
- Testing
- Tankevirus, Grubl
- Where
- Norway
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Akershus
Juvenile Idiopathic Arthritis (JIA)
Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis
The goal of this clinical trial is to learn whether children and adolescents with juvenile idiopathic arthritis (JIA) who have had inactive disease for a long time can safely discontinue treatment with a tumour necrosis factor…
- Trial name
- The Treat-JIA (NCT07904780)
- Testing
- Adalimumab, Etanercept, Golimumab
- Where
- 3 sites in Norway
- Volunteers
- 90 people
- Sponsor
- Oslo University Hospital
Thoracolumbar Burst Fracture
StUdy oN Burst Fractures (SunBurst)
Thoracolumbar (TL) burst fractures are seen in all ages and usually associated with high-energy trauma. Treatment include both surgical and non-surgical options.
- Trial name
- SunBurst (NCT05003180)
- Testing
- Surgical stabilization
- Where
- 17 sites in Norway, Sweden
- Volunteers
- 202 people
- Sponsor
- Uppsala University
Multiple Sclerosis
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety…
- Trial name
- OLERO (NCT05269004)
- Testing
- Ocrelizumab
- Where
- 232 sites in United States, Argentina and 35 more
- Volunteers
- 1,300 people
- Sponsor
- Hoffmann-La Roche
Lung Transplant Rejection
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of…
- Trial name
- ROCKaspire (NCT06082037)
- Testing
- Belumosudil, Azithromycin
- Where
- 85 sites in United States, Australia and 18 more
- Volunteers
- 180 people
- Sponsor
- Sanofi
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or…
- Trial name
- FIBRONEER™-ON (NCT06238622)
- Testing
- Nerandomilast
- Where
- 375 sites in United States, Argentina and 42 more
- Volunteers
- 1,666 people
- Sponsor
- Boehringer Ingelheim
Hepatobiliary Cancers
Observational Study Protocol: LIVER-R
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications.
- Trial name
- LIVER-R (NCT06252753)
- Testing
- Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings
- Where
- 161 sites in United States, Australia and 20 more
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Effects of Medisinstart for Type 2 Diabetes
Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up appointments with a pharmacist.
- Trial name
- NCT06273657
- Testing
- Medisinstart
- Where
- 22 sites in Norway
- Volunteers
- 500 people
- Sponsor
- Apokus AS
Spinal Cord Injuries, Myelopathy
Efficacy of rTMS Treatment After Spinal Cord Injury
There is accumulating evidence that neuromodulation by repetitive transcranial magnetic stimulation (rTMS) of the motor cortex holds promise as a treatment for rehabilitation of motor function following a spinal cord injury.
- Trial name
- NCT06464744
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- Norway
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Solid Tumours
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study.
- Trial name
- NCT06581432
- Testing
- Zongertinib
- Where
- 92 sites in United States, Australia and 14 more
- Volunteers
- 588 people
- Sponsor
- Boehringer Ingelheim
Sepsis
Aminoglycosides in Early Sepsis
Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are…
- Trial name
- AGES (NCT06712641)
- Testing
- Gentamicin + narrow spectrum betalactam, Cefotaxime, Piperacillin-tazobactam
- Where
- 15 sites in Norway
- Volunteers
- 1,900 people
- Sponsor
- University Hospital, Akershus
Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study.
- Trial name
- NCT06806592
- Testing
- Nerandomilast
- Where
- 153 sites in United States, Australia and 14 more
- Volunteers
- 414 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Hypertension
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Trial name
- NCT07064473
- Testing
- Vicadrostat, Empagliflozin
- Where
- 1,142 sites in United States, Argentina and 49 more
- Volunteers
- 11,800 people
- Sponsor
- Boehringer Ingelheim
Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07220083
- Testing
- BI 764198
- Where
- 316 sites in United States, Argentina and 38 more
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Proteinuric Kidney Diseases
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minimal change disease (TR-pMCD), Alport Syndrome (AS), and…
- Trial name
- NCT07355296
- Testing
- BI 764198
- Where
- 154 sites in United States, Argentina and 30 more
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves…
- Trial name
- NCT07472517
- Testing
- obrixtamig, atezolizumab, carboplatin
- Where
- 243 sites in United States, Argentina and 40 more
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Extrapulmonary Neuroendocrine Cancer (epNEC)
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves…
- Trial name
- NCT07544654
- Testing
- Obrixtamig, Carboplatin, Etoposide
- Where
- 168 sites in United States, Argentina and 27 more
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Embolism Acute
Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism
High-risk pulmonary embolism is a life-threatening condition requiring immediate reperfusion therapy. Full-dose systemic thrombolysis is recommended as first-line treatment, but its use is limited by the risk of major bleeding…
- Trial name
- REDSTEM (NCT07816978)
- Testing
- Reduced-dose alteplase, Full-dose alteplase
- Where
- 23 sites in Denmark, Norway and 1 more
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
Smoking Cessation, Smoking Cessation Counselling
New Smoking Cessation Intervention in Primary Care - a Randomized Controlled Trial
Cigarette smoking remains the leading modifiable risk factor for lung cancer4 and 16 other types of cancer, as well as chronic cardiovascular and pulmonary diseases.
- Trial name
- NCT07900724
- Testing
- WillQuit App, Smoking cessation standard treatment,
- Where
- Norway
- Volunteers
- 620 people
- Sponsor
- Helse Nord-Trøndelag HF
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.